MindMed adds a psychedelics therapy expert to its LSD research program.
4 Palliative Canadians approved for end of life psilocybin therapy through section 56(1) ; First legal medical exemptions for psilocybin in Canada since 1970s
LEGAL use of psilocybin in Canada for the first time in nearly 50 years.
Mindleap Health™ Expands its Digital Mental Health Programs for Addiction, Psychedelic Integration and Holistic Wellness
Mydecine's Vancouver-based affiliate, Mindleap Health™ is adding three digital therapy programs.
Going To War For Legal Psychedelic Drugs
The need for the medicinal benefits of psychedelic drugs is producing unlikely allies.
Novamind Closes the Acquisition of Cedar Psychiatry, a Leading Psychedelic Therapy Organization in the U.S.
Novamind acquires Utah-based Cedar Psychiatry and Cedar Clinical Research for CAD$3.05 million.
Palliative Canadians endure punishing waits while Health Minister delays approval of Psilocybin mushrooms; TheraPsil expands effort to Ontario
More pressure on Ottawa to move forward on legalization of psilocybin.
Big Pharma: Friend or Foe of Psychedelic Drugs?
Big Pharma has strong incentives to embrace psychedelics. But will its predatory business model turn drug companies against these drugs?
Numinus and Together We Can Partner to Support Addiction Recovery and Mental Wellness
Numinus establishes a partnership with one of Canada's largest addiction treatment organizations.
MindMed Completes Dosing 18-MC Phase 1 Study
MindMed completes its Phase 1 study of its non-hallucinogenic formulation of ibogaine.
Mydecine Building Its Psychedelics Footprint
Mydecine Innovations Group has been building momentum with a string of recent announcements.
Psychedelics Investing 101: Creating a Basket of Psychedelics Stocks
Intelligent diversification is the key to investing in this emerging industry.
Red Light Holland Provides Corporate Update
Red Light Holland released a detailed corporate update that includes operational and financial highlights as well as recent appointments.
